219 related articles for article (PubMed ID: 30130330)
21. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
22. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.
Kumar D; Chernenko S; Moussa G; Cobos I; Manuel O; Preiksaitis J; Venkataraman S; Humar A
Am J Transplant; 2009 May; 9(5):1214-22. PubMed ID: 19422346
[TBL] [Abstract][Full Text] [Related]
23. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
[TBL] [Abstract][Full Text] [Related]
25. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
26. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.
Chiereghin A; Gabrielli L; Zanfi C; Petrisli E; Lauro A; Piccirilli G; Baccolini F; Dazzi A; Cescon M; Morelli MC; Pinna AD; Landini MP; Lazzarotto T
Transplant Proc; 2010; 42(1):69-73. PubMed ID: 20172283
[TBL] [Abstract][Full Text] [Related]
27. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
28. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
[TBL] [Abstract][Full Text] [Related]
29. Effect of delaying prophylaxis against CMV in D+/R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martin-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM; ;
J Infect; 2015 Nov; 71(5):561-70. PubMed ID: 26183297
[TBL] [Abstract][Full Text] [Related]
30. Comparison of intracellular cytokine staining versus an ELISA-based assay to assess CMV-specific cell-mediated immunity in high-risk kidney transplant recipients.
Fernández-Ruiz M; Redondo N; Parra P; Ruiz-Merlo T; Rodríguez-Goncer I; Polanco N; González E; López-Medrano F; San Juan R; Navarro D; Andrés A; Aguado JM
J Med Virol; 2023 Apr; 95(4):e28733. PubMed ID: 37185851
[TBL] [Abstract][Full Text] [Related]
31. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
[TBL] [Abstract][Full Text] [Related]
32. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.
Ge S; Karasyov A; Sinha A; Petrosyan A; Lovato D; Thomas DL; Vo A; Jordan SC; Toyoda M
Transplantation; 2017 Jul; 101(7):1720-1726. PubMed ID: 27841845
[TBL] [Abstract][Full Text] [Related]
34. Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation.
Leone F; Gigliotti P; Mauro MV; Lofaro D; Greco F; Tenuta R; Perugini D; Papalia T; Mollica A; Perri A; Vizza D; La Russa A; Toteda G; Lupinacci S; Giraldi C; Bonofiglio R
Transpl Infect Dis; 2016 Apr; 18(2):191-201. PubMed ID: 26878346
[TBL] [Abstract][Full Text] [Related]
35. The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.
Low CY; Hosseini-Moghaddam SM; Rotstein C; Renner EL; Husain S
Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28613442
[TBL] [Abstract][Full Text] [Related]
36. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.
López-Oliva MO; Martinez V; Buitrago A; Jiménez C; Rivas B; Escuin F; Santana MJ; Selgas R; Bellón T
Transplantation; 2014 Apr; 97(8):839-45. PubMed ID: 24345896
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
38. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
39. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
Luan FL
Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
[TBL] [Abstract][Full Text] [Related]
40. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
